Sanofi (NASDAQ:SNY) Shares Bought by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 10.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 71,179 shares of the company's stock after acquiring an additional 6,893 shares during the period. Orion Portfolio Solutions LLC's holdings in Sanofi were worth $3,433,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Boston Partners boosted its stake in Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after acquiring an additional 2,501,073 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Sanofi by 13.1% in the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company's stock valued at $208,106,000 after purchasing an additional 395,744 shares during the period. Magnetar Financial LLC grew its stake in Sanofi by 104.3% during the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock worth $161,103,000 after buying an additional 1,705,148 shares during the last quarter. Natixis Advisors LLC increased its position in Sanofi by 1.2% during the fourth quarter. Natixis Advisors LLC now owns 2,910,021 shares of the company's stock worth $140,350,000 after buying an additional 35,828 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Sanofi in the fourth quarter valued at approximately $135,933,000. Hedge funds and other institutional investors own 14.04% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SNY. The Goldman Sachs Group initiated coverage on shares of Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 target price on the stock. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Finally, StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $62.50.

Remove Ads

Sanofi Stock Performance

SNY traded down $1.12 during trading on Tuesday, hitting $54.34. The stock had a trading volume of 3,810,197 shares, compared to its average volume of 2,276,146. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company's 50-day moving average price is $55.28 and its 200 day moving average price is $52.73. The firm has a market capitalization of $137.91 billion, a P/E ratio of 21.82, a PEG ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, equities research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.